Get Connected:

 

Latest News

Formulary Exclusion List Savings Analysis Highlights AJPB Week in Review
Top articles of the week from The American Journal of Pharmacy Benefits.
More Americans are able afford to fill their prescriptions following healthcare legislation.
 
The drug PZM21 could potentially provide pain relief without addiction risk.
 
The Sapien XT and Sapien 3 have received expanded indications for patients with aortic valve stenosis.  
 
A consensus about margins could reduce healthcare costs for patients with ductal carcinoma in-situ.
 
Researchers have discovered a mechanism that allows cancer cells to survive without nutrients.
 
Recently discovered protein function may improve outcomes in bone marrow transplants.
 
Top news of the day from across the healthcare landscape.
 
View More >

From the Journals

This study examines variations in overall use, and potentially inappropriate use, of non-warfarin direct-acting oral anticoagulants across sites within the Veterans Health Administration.
Individuals with treatment-resistant depression do not achieve and sustain remission after multiple pharmacotherapies, with an unknown impact on employment. This study investigates the expenditures of TRD from a private-payer perspective in Canada.
This study highlights the implications of noncompliance with the use of in-network providers for immunization services, shedding light on value-based benefits design to promote access to recommended vaccinations.
 
Specialty-focused partial-fill plan designs are gaining traction, with conflicting opinions on whether they reduce waste or impact the quality of care.
This study seeks to determine the economic effects of warfarin discontinuation in patients with nonvalvular atrial fibrillation.
This study evaluates whether provider adoption and use of formulary decision support for e-prescribing are directly associated with significant prescriber and patient behavior change.
The development and implementation of a rare disease management program by healthcare providers and payors could greatly assist in improving the clinical, psycho-social and economic impacts for this patient population.